Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Healthcare worker administering a vaccine to a patient © Steven Cornfield on Unsplash

While this is expected to improve with the second dose, this important finding may help influence the design of future vaccination strategies, with further work needed to determine the optimal interval between vaccine doses in certain groups.

The team from the University of Oxford’s MRC-Weatherall Institute of Molecular Medicine (MRC-WIMM) Molecular Haematology Unit studied 60 patients with chronic myeloid blood cancers under the care of the Myeloid Team at the Churchill Hospital, Oxford University Hospitals NHS Foundation Trust.

The study, published in the British Journal of Haematology, was supported by the NIHR Oxford Biomedical Research Centre.

Read the full story on the Radcliffe Department of Medicine website

The story is also featured on the NIHR Oxford Biomedical Research Centre website

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.